Submissions

Allergy & Anaphylaxis Australia (A&AA) is a charitable, non-profit organisation established in 1993 to support and assist those affected by allergy and anaphylaxis. A&AA is dedicated to assisting individuals, their caregivers and all in the community in the management of allergic conditions including food allergy. A&AA’s aim is to enable individuals and their families to enjoy an optimal quality of life whilst minimising risk to their health and wellbeing. A&AA strives to raise awareness of allergy in the community and provides evidence-based information, resources and services to support children and adults living with allergic disease including food allergy.

Select a link below to access A&AA's submission.

Mepolizumab Injection (Nucala®) to include use for chronic rhinosinusitis with nasal polyps - 17 Sep 2021

Allergy & Anaphylaxis Australia to made a submission to the Pharmaceutical Benefits Advisory Committee (PBAC) on change ot Pharmaceutical Benefits Scheme listing of Mepolizumab Injection (Nucala®) to include use for people diagnosed with chronic rhinosinusitis with nasal polyps. A&AA Mepolizumab Injection (Nucala) change of PBS listing Sep 2021179.29...

ABROCITINIB Cibinqo® submission supporting PBS Listing for severe atopic dermatitis - 13 Sep 2021

Allergy & Anaphylaxis Australia to made a submission to the Pharmaceutical Benefits Advisory Committee (PBAC) on Pharmaceutical Benefits Scheme listing of ABROCITINIB Tablet 100 mg Tablet 200 mg Cibinqo® for severe atopic dermatitis. A&AA Abrocitinib Submission Sep 2021179.99 KB

Upadacitinib (Rinvoq®) for the treatment of chronic severe atopic dermatitis (AD) - 25 May 2021

Allergy & Anaphylaxis Australia to made a submission to the Pharmaceutical Benefits Advisory Committee (PBAC) on Pharmaceutical Benefits Scheme listing of Upadacitinib (Rinvoq®) for the treatment of chronic severe atopic dermatitis (AD). A&AA Upadacitinib Rinvoq Submission May 2021183.25 KB

Baricitinib (Olumiant®) for the treatment of chronic severe atopic dermatitis (AD) - 25 May 2021

Allergy & Anaphylaxis Australia made a submission to to Pharmaceutical Benefits Advisory Committee (PBAC) on Pharmaceutical Benefits Scheme (PBAC) listing of Baricitinib (Olumiant®) for the treatment of chronic severe atopic dermatitis (AD). A&AA Baricitinib Olumiant Submission May 2021167.27 KB

Building a more robust medicine supply: Proposals -16 May 2021

Allergy & Anaphylaxis Australia (A&AA) made a submission to Therapeutic Good Administrations (TGA) on Building a more robust medicine supply - Proposals to help prevent, mitigate and manage medicine shortages with the following proposals: Proposal 1 – Prioritising evaluation of important generic medicines Proposal 3 – Improving reliability of supply...

General Standard for the Labelling of Pre-packaged Foods (CXS 1 1985) - 2 Mar 2021

Allergy & Anaphylaxis Australia (A&AA) made a submission with regard to Request for comments / information on allergen labelling: revision of the General Standard for the Labelling of Pre-packaged Foods (CXS 1 1985) (For further information please see CL 2021/9/OCS-FL). CONSULTATION QUESTIONS Question 1 Does the scope of the GSLPF need clarifying...

Budesonide (Jorveza®) for use in EoE (Eosinophilic Oesoghagitis) - 8 Feb 2021

Allergy & Anaphylaxis Australia (A&AA) made a submission to Pharmaceutical Benefits Advisory Committee (PBAC). Eosinophilic Oesophagitis (EoE) currently affects about 1 in 1000 Australians¹ (both children and adults). It is a debilitating disease that has no cure. The symptoms of EoE are varied and include difficulty swallowing and food sticking in the...

Irradiation as a phytosanitary measure for all fresh fruit and vegetables - 7 Dec 2020

Allergy & Anaphylaxis Australia (A&AA) made a submission to Food Standards Australia New Zealand re: Application A1193 - Irradiation as a phytosanitary measure for all fresh fruit and vegetables. Summary: A&AA strongly encourages Food Standards Australia New Zealand (FSANZ) to seek advice on issues surrounding irradiation of fruit and vegetables,...

Beta-amylase from soybean (Glycine max) as a processing aid (enzyme) - 7 Dec 2020

Allergy & Anaphylaxis Australia (A&AA) made a submission to Food Standards Australia New Zealand re: Application A1204 - Beta-amylase from soybean (Glycine max) as a processing aid (enzyme). Summary: A&AA is not opposed to the application, but has issues and concerns which do not appear to have been fully addressed. The labelling obligation seem...

Review of the Food Standards Australia New Zealand Act 1991 - 16 Nov 2020

Allergy & Anaphylaxis Australia (A&AA) made a submission to Public Consultation - Scoping Paper on the Review of the Food Standards Australia New Zealand Act 1991. A&AA has responded to the discussion questions and the reform ideas predominately as they relate to FSANZ’s approach to food allergens and persons with one or more food allergy. Some...

A&AA Submission to Parliamentary inquiry - 3 Nov 2020

Background Allergy & Anaphylaxis Australia (A&AA) is a registered charity, established in 1993 to support and assist those affected by allergy and anaphylaxis. A&AA is dedicated to assisting individuals, their caregivers and all in the community in the management of allergic conditions including food allergy. A&AA’s aim is to enable individuals...

Application A1186 Soy leghemoglobin in meat analogue products 16 Sep

Allergy & Anaphylaxis Australia (A&AA) made a submission to Food Standards Australia New Zealand (FSANZ) Application A1186 Soy leghemoglobin in meat analogue products 16 Sep156.6 KB

SYMJEPI® adrenaline (epinephrine) injector application 9 Sep 2020

Allergy & Anaphylaxis Australia (A&AA) made a submission to Pharmaceutical Benefits Advisory Committee (PBAC) SYMJEPI® adrenaline (epinephrine) injector application 9 Sep 2020

Anapen® adrenaline (epinephrine) autoinjector application 8 Sep 2020

Allergy & Anaphylaxis Australia (A&AA) made a submission to Pharmaceutical Benefits Advisory Committee (PBAC) Anapen® adrenaline (epinephrine) autoinjector application 8 Sep 2020

Dupilumab (Dupixent®) for severe, uncontrolled asthma 8 Sep 2020

Allergy & Anaphylaxis Australia (A&AA) made a submission to Pharmaceutical Benefits Advisory Committee (PBAC) Dupilumab (Dupixent®) for severe, uncontrolled asthma 8 Sep 2020190.06 KB

Rapeseed protein isolate as a novel food 28 August 2020

Allergy & Anaphylaxis Australia (A&AA) made a submission to Food Standards Australia New Zealand (FSANZ) Submission on A1175 – Rapeseed protein isolate as a novel food263.67 KB

Parliamentary inquiry into allergies and anaphylaxis in Australia

Submission from Allergy & Anaphylaxis Australia In August this year, Minister for Health the Hon Greg Hunt MP announced that a Parliamentary Inquiry into allergies and anaphylaxis would be undertaken by the Standing Committee on Health. Allergy & Anaphylaxis Australia's Parliamentary Inquiry Submission has now been lodged and published. You can read...

Review of Food Standards Code chapters 3 and 4 - Food Safety Management requirements

Submission from Allergy & Anaphylaxis Australia Summary Allergy & Anaphylaxis Australia (A&AA) is deeply concerned that the Illness Reduction Strategy 2018 – 2021+ will seemingly not address allergic reactions on the basis that “allergens were not a defined hazard”. It also appears that there is little or no impetus through either Food Regulation...

Management and communication of medicines shortages

Submission to the Therapeutic Goods Administration (TGA) from Allergy & Anaphylaxis Australia 23 April 2018 Consultation: Management and communication of medicines shortages TGA Medication Shortages from A&AA 23-04-2018487.22 KB

Plain English Allergen Labelling (PEAL)

Submission from Allergy & Anaphylaxis Australia In March 2018 Food Standards Australia New Zealand (FSANZ) called for submissions on proposal (P1044) for Plain English Allergen Labelling (PEAL). A&AA’s submission was Plain English Allergen Labelling (PEAL)1.04 MB